Yulia Slavina

Active surveillance test upgraded with AI as Myriad Genetics integrates new features

Active surveillance test upgraded with AI as Myriad Genetics integrates new features
Myriad Genetics debuts AI test

Myriad Genetics has introduced an updated version of its test specifically designed for active surveillance, now enhanced with artificial intelligence capabilities.

The company urges healthcare providers to tailor active surveillance management for patients using this AI-powered solution. The new offering targets the fields of urology and prostate cancer, leveraging genetic insights to improve early detection and monitoring. The move underscores Myriad Genetics’ commitment to advancing genetic testing in clinical practice.

Earlier, Myriad Genetics announced the launch of its Prolaris plus AI test, combining molecular scores with digital pathology for prostate cancer diagnosis. The company has also introduced its Precise MRD test for advanced molecular residual disease detection. These efforts highlight Myriad’s continued focus on integrating AI and molecular insights into clinical testing.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.